Efficacy and safety of propiverine in cpomparison to oxybutynin in children with neurogenic detrusor overactivity: an observational study
© The Author(s) 2005
Published: 30 December 2005
Assessment of efficacy and safety of propiverine (prop.; Mictonetten™) and oxybutynin (oxy.) in children with neurogenic detrusor overactivity (NDO) aged 1 – 18 years.
Materials and methods
In a comparative cohort study 255 children with NDO (199 myelomeningocele (MMC), 46 spinal cord injury), were treated with anticholinergics for 2.5 years on average at 14 centers and were evaluated retrospectively. 127/255 children were allocated to prop., 128/255 to oxy.; median age at diagnosis and treatment initiation were 2.08 and 7.18 (prop.) vs. 3.37 and 7.98 (oxy) years, respectively.
Max. detrusor pressure at micturition (cm H20)
Compliance (ml/cm H20)
Max. bladder capacity (ml)
Catheterization frequency/24 h
Reflux left side (stage III–V) (N)
Reflux right side (stage III–V) (N)
Propiverine was better tolerated than oxybutynin (9.40 vs. 17.46% adverse events), in those children suffering from MMC significantly better.
Comparative studies of efficacy and tolerability of anticholinergics in NDO of children were missing so far. This cohort study demonstrates a more effective reduction of the max. detrusor pressure at micturition with prop. in comparison to oxy. Prop. was better tolerated than oxy. Urodynamic effects are correlated with improvement of reflux, indicating possibly more favourable long-term outcomes of the upper urinary tract
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.